Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Clues Emerge to Bone Health, Destruction in Rheumatoid Arthritis

Lara C. Pullen, PhD  |  Issue: December 2014  |  December 1, 2014

The microscopic view of the surface of bone is demonstrated. Osteoclasts are cylindrical cells seen in small cavities known as Howship’s lacuna. These cells resorb bone. Osteoblasts are seen as irregular shaped flattened cells and function to produce bone. As a result of these cells’ effect on bone, the microscopic surface appears irregular.
The microscopic view of the surface of bone is demonstrated. Osteoclasts are cylindrical cells seen in small cavities known as Howship’s lacuna. These cells resorb bone. Osteoblasts are seen as irregular shaped flattened cells and function to produce bone. As a result of these cells’ effect on bone, the microscopic surface appears irregular.

Osteoclasts are the bone-resorptive cells that play the key role in physiological skeleton development and homeostatic bone remodeling. Consequently, abnormal osteoclast function can lead to osteoporosis, rheumatoid arthritis (RA) and other diseases. Investigators are, thus, eager to learn what makes an osteoclast healthy and functioning and what can go wrong, thereby creating pathology. A new study provides a novel contribution to our understanding of osteoclast physiology: RBP-J is a key regulator of osteoclastogenesis and bone remodeling.

RBP-J is also known as CSL and CBF1. It is the recombinant recognition sequence binding protein at the Jk site. It is known to function as a central transcription factor, receiving signals from multiple signaling pathways. We now know that it also regulates bone remodeling. What makes the finding especially interesting is that the newly discovered RBP-J-centered signaling pathway appears to contribute to the development of the inflammatory bone erosion that is a hallmark of RA. The pathway also explains the mystifying results of a previous genome-wide association study that linked a variant in RBP-J with the development of RA.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The current research was performed by Baohong Zhao, PhD, assistant scientist in the Arthritis and Tissue Degeneration Program at the Hospital for Special Surgery in New York City and colleagues and published online Oct. 20 in the Journal of Clinical Investigation.1 In their paper, the investigators not only describe the signaling pathway, but also describe how environmental cues that modulate expression/function of the transcription factor RBP-J appear to influence osteoclast differentiation and bone remodeling.

A new study provides a novel contribution to our understanding of osteoclast physiology: RBP-J is a key regulator of osteoclastogenesis & bone remodeling.

What Has Previously Been Shown

Osteoclastogenesis begins with RANK signaling in osteoclast precursors, as well as costimulation from immunoreceptor tyrosine-based activation motif-containing (ITAM-containing) receptors/adaptors. The two main ITAM-containing tyrosine kinase binding proteins involved in this process are DNAX-activating protein 12 (DAP12) and Fc receptor common ɣ subunit (FcRɣ). These ITAM-adaptors are known to associate with various receptors and mediate signaling. Recent work has also revealed that the RANK- and ITAM-signaling pathways are integrated by a multiprotein signaling complex comprising BTK/TEC/BLNK/SLP76/PLCɣ2. Up until now, however, investigators have not known how the costimulatory signals are regulated and integrated with RANK signaling.

Where RBP-J Fits In

RBP-J controls excessive bone erosion through facilitation of RANK signaling. The ligand for RANK (RANKL) induces osteoclastogenesis, but to do this, it first requires calcium signaling to activate NFATc1. NFATc1 is established as the master regulator of osteoclastogenesis, and its activation requires sustained calcium signaling, as opposed to an acute and transient calcium flux. RBP-J provides sustained calcium signaling through the suppression of calcium fluctuations via a TGF-β/PLCɣ2/calcium axis. Moreover, after RANKL stimulation during osteoclastogenesis, RBP-J expression decreases.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:boneosteoclastosteoclastogenesisPullenResearchRheumatoid arthritis

Related Articles

    A Duet of Bone and the Immune System

    July 12, 2011

    Examining emerging perspectives in osteoimmunology

    New Treatments Needed to Prevent Fractures in Osteoporosis

    June 1, 2014

    Current therapies target pathways of bone remodeling, but rheumatologists say a better understanding of the mechanisms of bone resorption, formation is needed to make an impact

    T Cells in Systemic Lupus Erythematosus

    August 1, 2011

    Progress toward targeted therapy

    Build Up Bone

    June 1, 2007

    Current management of osteoporosis

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences